08329.HK
Shenzhen Neptunus Interlong Bio-technique Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.10
−6.67%Margins
Gross margin
29.1%
EBITDA margin
4.3%
EBIT margin
-4.8%
Net margin
-4.4%
FCF margin
11.8%
-7.5%
Return on equity
-4.6%
Return on assets
-7.1%
Return on invested capital
1.05x
Asset turnover
HKD 168.9M
Cash from operations
HKD 0.15
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026